Eris Lifesciences Limited — Others, 22-08-2025: Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Eris Lifesciences has received a show cause cum demand notice from GST Intelligence, alleging non-payment of IGST amounting to approximately 16.85 Cr. This relates to the import of services for its 2019 acquisition of "Zomelis" trademark rights from Novartis AG Switzerland. The notice also includes applicable interest at 18% per annum from November 27, 2019. The company is evaluating the notice with its tax consultants and plans to submit a reply. It is confident that it has complied with GST laws and expects the demand not to be upheld, minimizing any potential financial impact.